Clinical Trials Logo

Clinical Trial Summary

This study will assess the safety and efficacy of LFG316 in patients with age related macular degeneration.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01535950
Study type Interventional
Source Novartis
Contact
Status Completed
Phase Phase 2
Start date February 2012
Completion date July 2013

See also
  Status Clinical Trial Phase
Completed NCT01835067 - Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular AMD Phase 2/Phase 3
Completed NCT01674569 - Pilot Study of X-82 in Patients With Wet AMD Phase 1/Phase 2
Recruiting NCT04504123 - MMP-9 Inhibition for Recalcitrant Wet AMD Phase 2
Completed NCT01473251 - Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular Degeneration N/A
Recruiting NCT05093374 - Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting Phase 4
Completed NCT01617148 - Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept Phase 4
Completed NCT02287298 - Triple Combination Therapy of Choroidal Neovascularization in AMD, a Cost Effect and Efficient Therapeutic Treatment N/A
Active, not recruiting NCT03803631 - CNV in AMD Analyzed by OCT Angiography Under IntravitreaL Eylea (COCTAEyl)